ASCO GU 2022 - Results from #240

Viewing 241-260 of 316 articles

ASCO GU 2022: Community Oncologists’ Perceptions of and Barriers To Access for 177LU-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2022: Randomized Phase II Trial of Neoadjuvant Abiraterone Plus or Minus Cabazitaxel in High-Risk Prostate Cancer: ACDC-RP

ASCO GU 2022: Clinical and Molecular Features of Low PSMA Expression in Patients With Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2022: Mechanisms of Resistance to Radiopharmaceuticals

ASCO GU 2022: TALAPRO-1: Talazoparib Monotherapy in mCRPC With Tumor DNA Damage Response Alterations —Exploration of Germline DDR Alteration Landscape and Potential Associations With Antitumor Activity

ASCO GU 2022: Discussion - PROpel and MAGNITUDE

ASCO GU 2022: Updated Biomarker Results From a Phase 1/2 Study of Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)

ASCO GU 2022: Phase 1 Results of the ODM-208 First-in-Human Phase 1–2 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer (CYPIDES)

ASCO GU 2022: PSMA PET and FDG PET as Predictors of Response and Prognosis in a Randomized Phase 2 Trial of 177Lu-PSMA-617 Versus Cabazitaxel in mCRPC Progressing after Docetaxel: TheraP ANZUP 1603

ASCO GU 2022: BXCL701: First-in-Class Oral Activator of Systemic Innate Immunity Combined With Pembrolizumab, in Patients With mCRPC of Small-Cell Neuroendocrine Carcinoma Phenotype, Phase 2a Interim Results

ASCO GU 2022: Bone Mineral Density in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer Treated With or Without Abiraterone Plus Prednisone in the PEACE-1 Phase 3 Trial

ASCO GU 2022: Beyond Prostate-Specific Membrane Antigen: New Targets in Prostate Cancer

ASCO GU 2022: CYCLONE 2: A Phase 2/3, Randomized, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or Without Abemaciclib in Patients with mCRPC

ASCO GU 2022: Detection Rate of 18F-rhPSMA-7.3 PET in Patients with Suspected Prostate Cancer Recurrence: Results from a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)

ASCO GU 2022: PRESIDE, a Randomized, Double-Blind, Placebo-Controlled, Phase 3b Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy-Naïve, mCRPC Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on ENZA

Positive Results from Phase III Investigational Trial Shows NUBEQA® (darolutamide) Plus Androgen Deprivation Therapy (ADT) and Docetaxel Significantly Increases Overall Survival (OS) in Patients with mHSPC

ASCO GU 2022: ARASENS Trial Overall Survival With Darolutamide Versus Placebo in Combination With ADT and Docetaxel for mHSPC

ASCO GU 2022: First Results of the MAGNITUDE: Phase 3 Study of Niraparib With Abiraterone Acetate and Prednisone As First-Line Therapy in Patients With mCRPC With and Without HRR Gene Alterations

ASCO GU 2022: Serial Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer Detected by PET Imaging

ASCO GU 2022: Overall Survival With Darolutamide Versus Placebo in Combination With Docetaxel and Androgen-Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in the Phase 3 ARASENS Trial

7
8
9
10
11
12
13
14
15
16